Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation

Oncogene

Volumn 31, Issue 13, 2012, Pages 1733-1742

  Takai, A ^a   Marusawa, H ^a   Minaki, Y ^a   Watanabe, T ^a   Nakase, H ^a   Kinoshita, K ^b   Tsujimoto, G ^a   Chiba, T ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Shiga Medical Center Research Institute   (Japan)

Author keywords

AID; colitis associated cancer; colonic inflammation; IL 10 mouse

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ETANERCEPT; INTERLEUKIN 10; INTERLEUKIN 12; RECOMBINANT ANTIBODY; RECOMBINANT INTERLEUKIN 12P40 MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CECUM; CECUM CANCER; COLITIS; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

ANIMALS; CECUM; COLITIS; COLONIC NEOPLASMS; CYTIDINE DEAMINASE; INTERLEUKIN-10; MICE; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84859426818     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.352     Document Type: Article

References (44)

1. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. (2010). B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464: 302-305.
2. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G et al. (1996). Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98: 1010-1020. (Pubitemid 26293320)
3. Bhutani N, Brady JJ, Damian M, Sacco A, Corbel SY, Blau HM. (2010). Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 463: 1042-1047.
4. Chiba T, Marusawa H. (2009). A novel mechanism for inflammation- associated carcinogenesis; an important role of activation-induced cytidine deaminase (AID) in mutation induction. J Mol Med 87: 1023-1027.
5. Chiba T, Seno H, Marusawa H, Wakatsuki Y, Okazaki K. (2006). Host factors are important in determining clinical outcomes of Helicobacter pylori infection. J Gastroenterol 41: 1-9.
6. Davidson NJ, Leach MW, Fort MM, Thompson-Snipes L, Kuhn R, Muller W et al. (1996). T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 184: 241-251. (Pubitemid 26247233)
7. Eaden JA, Abrams KR, Mayberry JF. (2001). The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526-535. (Pubitemid 32234798)
8. Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, Okazaki IM et al. (2007). Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene 26: 5587-5595. (Pubitemid 47267836)
9. Endo Y, Marusawa H, Kou T, Nakase H, Fujii S, Fujimori T et al. (2008). Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology 135: 889-898, 898 e1-3.
10. Fagarasan S, Kinoshita K, Muramatsu M, Ikuta K, Honjo T. (2001). In situ class switching and differentiation to IgA-producing cells in the gut lamina propria. Nature 413: 639-643. (Pubitemid 32964064)
11. Fagarasan S, Muramatsu M, Suzuki K, Nagaoka H, Hiai H, Honjo T. (2002). Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science 298: 1424-1427. (Pubitemid 35346143)
12. Fearon ER, Vogelstein B. (1990). A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
13. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA et al. (1996). Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157: 1261-1270. (Pubitemid 126449643)
14. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F et al. (2009). Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361: 2033-2045.
15. Guo JU, Su Y, Zhong C, Ming GL, Song H. (2011). Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145: 423-434.
16. Holzmann K, Klump B, Borchard F, Hsieh CJ, Kuhn A, Gaco V et al. (1998). Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int J Cancer 76: 1-6. (Pubitemid 28164560)
17. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP et al. (2000). Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60: 3333-3337. (Pubitemid 30482141)
18. Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y et al. (2007). Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 146: 649-656. (Pubitemid 351650520)
19. Inoue S, Nakase H, Matsuura M, Mikami S, Ueno S, Uza N et al. (2009). The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol 156: 172-182.
20. Kern SE, Redston M, Seymour AB, Caldas C, Powell SM, Kornacki S et al. (1994). Molecular genetic profiles of colitis-associated neoplasms. Gastroenterology 107: 420-428. (Pubitemid 24233316)
21. Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T et al. (2008). Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 47: 888-896. (Pubitemid 351449680)
22. Kou T, Marusawa H, Kinoshita K, Endo Y, Okazaki IM, Ueda Y et al. (2007). Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int J Cancer 120: 469-476. (Pubitemid 44969015)
23. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. (1993). Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274. (Pubitemid 23320290)
24. Lashner BA, Shapiro BD, Husain A, Goldblum JR. (1999). Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol 94: 456-462. (Pubitemid 29084669)
25. Leedham SJ, Graham TA, Oukrif D, McDonald SA, Rodriguez-Justo M, Harrison RF et al. (2009). Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 136: 542-550 e6.
26. Lin WW, Karin M. (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183.
27. Liu R, Bal HS, Desta T, Behl Y, Graves DT. (2006). Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am J Pathol 168: 757-764. (Pubitemid 43327728)
28. Mantovani A, Allavena P, Sica A, Balkwill F. (2008). Cancer-related inflammation. Nature 454: 436-444.
29. Marra F, Valente AJ, Pinzani M, Abboud HE. (1993). Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. J Clin Invest 92: 1674-1680. (Pubitemid 23304529)
30. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T et al. (2007). Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 13: 470-476. (Pubitemid 46559833)
31. Morisawa T, Marusawa H, Ueda Y, Iwai A, Okazaki IM, Honjo T et al. (2008). Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression. Int J Cancer 123: 2735-2740.
32. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. (2000). Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553-563.
33. Nakatani T, Mizuhara E, Minaki Y, Sakamoto Y, Ono Y. (2004). Helt, a novel basic-helix-loop-helix transcriptional repressor expressed in the developing central nervous system. J Biol Chem 279: 16356-16367. (Pubitemid 38509332)
34. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. (1996). Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 2: 998-1004. (Pubitemid 26306838)
35. Podolsky DK. (2002). Inflammatory bowel disease. N Engl J Med 347: 417-429.
36. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S et al. (2008). Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118: 560-570. (Pubitemid 351206546)
37. Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR. (2008). DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 135: 1201-1212.
38. Redston MS, Papadopoulos N, Caldas C, Kinzler KW, Kern SE. (1995). Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology 108: 383-392.
39. Sturlan S, Oberhuber G, Beinhauer BG, Tichy B, Kappel S, Wang J et al. (2001). Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 22: 665-671. (Pubitemid 32288669)
40. Suzuki K, Meek B, Doi Y, Muramatsu M, Chiba T, Honjo T et al. (2004). Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci USA 101: 1981-1986. (Pubitemid 38229001)
41. Takai A, Toyoshima T, Uemura M, Kitawaki Y, Marusawa H, Hiai H et al. (2009). A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations. Oncogene 28: 469-478.
42. Toda Y, Kono K, Abiru H, Kokuryo K, Endo M, Yaegashi H et al. (1999). Application of tyramide signal amplification system to immunohistochemistry: a potent method to localize antigens that are not detectable by ordinary method. Pathol Int 49: 479-483. (Pubitemid 29309683)
43. Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, Strober W. (2006). Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigens-pecific colitis. Immunity 25: 473-485. (Pubitemid 44355006)
44. Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD et al. (1993). p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 104: 1633-1639. (Pubitemid 23235452)